Zacks Investment Research lowered shares of Abcam PLC (NASDAQ:ABCZY) from a buy rating to a hold rating in a report issued on Monday.
According to Zacks, “Abcam PLC distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam PLC is headquartered in Cambridge, the United Kingdom. “
Abcam PLC (NASDAQ:ABCZY) opened at 13.8275 on Monday. Abcam PLC has a one year low of $9.13 and a one year high of $15.22. The firm has a market capitalization of $2.82 billion and a P/E ratio of 50.4653. The firm has a 50-day moving average price of $14.16 and a 200-day moving average price of $12.78.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Equities Focus and is the property of of Equities Focus. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.equitiesfocus.com/2017/10/05/abcam-plc-abczy-downgraded-by-zacks-investment-research.html.
Get a free copy of the Zacks research report on Abcam PLC (ABCZY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abcam PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam PLC and related companies with MarketBeat.com's FREE daily email newsletter.